JG
VRTX icon

Jefferies Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Jefferies Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$57.9K Hold
200
– – ﹤0.01% 1503
2022
Q2 		$56.4K Buy
+200
New +$53.5K ﹤0.01% 1394
2022
Q1 		– Sell
-85,000
Closed -$18.7M – 1968
2021
Q4 		$18.7M Hold
85,000
– – 0.11% 149
2021
Q3 		$15.4M Buy
85,000
+60,000
+240% +$11.7M 0.11% 168
2021
Q2 		$5.04M Hold
25,000
– – 0.03% 463
2021
Q1 		$5.37M Buy
+25,000
New +$5.49M 0.05% 356
2020
Q2 		– Sell
-11,700
Closed -$2.78M – 2077
2020
Q1 		$2.78M Sell
11,700
-20,200
-63% -$4.63M 0.03% 523
2019
Q4 		$6.99M Sell
31,900
-22,000
-41% -$4.45M 0.05% 370
2019
Q3 		$9.13M Buy
+53,900
New +$9.54M 0.07% 258
2019
Q1 		– Sell
-80,700
Closed -$13.4M – 2664
2018
Q4 		$13.4M Buy
+80,700
New +$14M 0.11% 142
2018
Q3 		– Sell
-140,000
Closed -$23.8M – 2772
2018
Q2 		$23.8M Buy
+140,000
New +$21.7M 0.13% 98
2017
Q2 		– Sell
-189,200
Closed -$20.7M – 2597
2017
Q1 		$20.7M Buy
+189,200
New +$16.7M 0.15% 107
2016
Q1 		– Sell
-61,000
Closed -$7.68M – 2597
2015
Q4 		$7.68M Buy
61,000
+48,500
+388% +$5.85M 0.04% 331
2015
Q3 		$1.3M Buy
12,500
+10,200
+443% +$1.31M 0.01% 1099
2015
Q2 		$284K Buy
+2,300
New +$290K ﹤0.01% 1802
2015
Q1 		– Sell
-221,400
Closed -$26.3M – 2418
2014
Q4 		$26.3M Buy
221,400
+110,000
+99% +$12.4M 0.15% 116
2014
Q3 		$12.5M Sell
111,400
-37,900
-25% -$3.61M 0.09% 202
2014
Q2 		$14.1M Buy
149,300
+61,200
+69% +$4.29M 0.12% 152
2014
Q1 		$6.23M Sell
88,100
-30,700
-26% -$2.43M 0.06% 249
2013
Q4 		$8.83M Buy
+118,800
New +$8.27M 0.06% 189
2013
Q3 		– Sell
-48,900
Closed -$3.92M – 2211
2013
Q2 		$3.92M Buy
+48,900
New +$3.6M 0.04% 306

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jefferies Group's VRTX Position: Q3 2022 in Review

Jefferies Group increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q3 2022, buying an estimated $95.2K and bringing the position to 1,447 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Jefferies Group first reported a position in VRTX in Q2 2013 and has held it in 35 quarters since. The position peaked at $15.4M in Q4 2014. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Jefferies Group held 1,447 shares of Vertex Pharmaceuticals worth $419K as of Q3 2022.
  • Jefferies Group bought 331 Vertex Pharmaceuticals shares in Q3 2022, an estimated $95.2K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1098 holding.
  • Jefferies Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Jefferies Group's Vertex Pharmaceuticals position peaked at $15.4M in Q4 2014.
  • 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.